PROSTOX test predicts urinary side effects in prostate cancer patients using microRNAs to assess genetic risk factors. The test identifies high-risk patients, who are 10 to 12 times more likely to ...

MiraDx Announces the Commercial Availability of PROSTOX™ ultra for Prediction of Risk of Late Genitourinary Toxicity in Prostate Cancer Patients Considering Radiation Therapy MiraDx, a molecular ...

- Study confirms previous published results showing that PROSTOX ultra accurately predicts late genitourinary toxicity and has significant correlation with genitourinary toxicity grade LOS ANGELES, ...

California-based molecular diagnostics company MiraDx has added Prostox Standard to its portfolio – marking another US launch in the company’s cancer testing portfolio. The diagnostic assay is ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which patients with prostate cancer are at higher risk of developing long-lasting ...

This study validated PROSTOX as predicting radiotherapy-induced genitourinary toxicity, which can be differentiated into acute and chronic with mirSNP-based signatures, in patients with prostate ...

New Publication Shows PROSTOX™ ultra Test Delivers Significant Health System Cost Savings and Quality-of-Life Gains for Prostate Cancer Patients Undergoing Radiation Therapy MiraDx, a molecular ...

LOS ANGELES, September 26, 2025--(BUSINESS WIRE)--MiraDx, a molecular diagnostics company advancing germline-based personalization of cancer treatment, announced today a study from UCLA that will be ...

LOS ANGELES, October 01, 2025--(BUSINESS WIRE)--MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, announced today that its PROSTOX ultra test is now ...